{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825894374220928.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1136/gut.2004.040675"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/gut.2004.040675"}}],"dc:title":[{"@value":"Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>\n                    <jats:bold>Background:</jats:bold>\n                    There is little information about the effect of infliximab on the clinical course of liver disease in Crohn’s disease patients with concomitant hepatitis B virus (HBV) infection. Theoretically, immunosuppression induced by infliximab will facilitate viral replication which could be followed by a flare or exacerbation of disease when therapy is discontinued. There are no specific recommendations on surveillance and treatment of HBV before infliximab infusion. Two cases of severe hepatic failure related to infliximab infusions have been described in patients with rheumatic diseases.\n                  </jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods:</jats:bold>\n                    Hepatitis markers (C and B) and liver function tests were prospectively determined to 80 Crohn’s disease patients requiring infliximab infusion in three hospitals in Spain.\n                  </jats:p>\n                  <jats:p>\n                    <jats:bold>Results:</jats:bold>\n                    Three Crohn’s disease patients with chronic HBV infection were identified. Two of the three patients with chronic HBV infection suffered severe reactivation of chronic hepatitis B after withdrawal of infliximab therapy and one died. A third patient, who was treated with lamivudine at the time of infliximab therapy, had no clinical or biochemical worsening of liver disease during or after therapy. From the remaining 80 patients, six received the hepatitis B vaccine. Three patients had antibodies to both hepatitis B surface antigen (anti-HBs) and hepatitis B core protein (anti-HBc) with normal aminotransferase levels, and one patient had positive anti-hepatitis C virus (HCV) antibodies, negative HCV RNA, and normal aminotransferase levels. Except for the patients with chronic HBV infection, no significant changes in hepatic function were detected.\n                  </jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:</jats:bold>\n                    Patients with Crohn’s disease who are candidates for infliximab therapy should be tested for hepatitis B serological markers before treatment and considered for prophylaxis of reactivation using antiviral therapy if positive.\n                  </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004053983238541","@type":"Researcher","foaf:name":[{"@value":"M Esteve"}]},{"@id":"https://cir.nii.ac.jp/crid/1380306508269251202","@type":"Researcher","foaf:name":[{"@value":"C Saro"}]},{"@id":"https://cir.nii.ac.jp/crid/1380306508269251201","@type":"Researcher","foaf:name":[{"@value":"F González-Huix"}]},{"@id":"https://cir.nii.ac.jp/crid/1380306508269251200","@type":"Researcher","foaf:name":[{"@value":"F Suarez"}]},{"@id":"https://cir.nii.ac.jp/crid/1380306508269251204","@type":"Researcher","foaf:name":[{"@value":"M Forné"}]},{"@id":"https://cir.nii.ac.jp/crid/1380306508269251203","@type":"Researcher","foaf:name":[{"@value":"J M Viver"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00175749"},{"@type":"EISSN","@value":"14683288"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00175749"}],"prism:publicationName":[{"@value":"Gut"}],"dc:publisher":[{"@value":"BMJ"}],"prism:publicationDate":"2004-08-11","prism:volume":"53","prism:number":"9","prism:startingPage":"1363","prism:endingPage":"1365"},"reviewed":"false","url":[{"@id":"https://syndication.highwire.org/content/doi/10.1136/gut.2004.040675"}],"createdAt":"2004-08-11","modifiedAt":"2025-11-21","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002215326388096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002218323019648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232087161856","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004233980469120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283691784950144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus–induced lipid alterations contribute to natural killer T cell–dependent protective immunity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580230619629312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205297032320","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Evaluation of Hepatitis B Vaccination in Nursing School Students"},{"@language":"ja","@value":"看護学生に対するB型肝炎ワクチン接種の評価"},{"@language":"ja-Kana","@value":"カンゴ ガクセイ ニ タイスル Bガタ カンエン ワクチン セッシュ ノ ヒョウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679753835520","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"関節リウマチに用いる生物学的製剤による重篤な感染症の解析"},{"@language":"en","@value":"Signal Detection of Serious Infections Following Treatment with Biologics for Rheumatoid Arthritis:"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367073795072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1136/gut.2004.040675"},{"@type":"CROSSREF","@value":"10.1007/s00535-010-0367-5_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0464-7_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.00998.x_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.1016/j.crohns.2013.08.008_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.1074/jbc.m113.501122_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.4058/jsei.27.253_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.1038/nm.2811_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.40.586_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"},{"@type":"CROSSREF","@value":"10.1111/hepr.13798_references_DOI_C6ysf6wgPptiaDOv6yn5XQ9rGgJ"}]}